Secukinumab

CAS No. 875356-43-7

Secukinumab( —— )

Catalog No. M22161 CAS No. 875356-43-7

Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 487 In Stock
10MG 692 In Stock
25MG 1026 In Stock
50MG 1386 In Stock
100MG 1832 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Secukinumab
  • Note
    Research use only, not for human use.
  • Brief Description
    Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
  • Description
    Secukinumab is a fully humanized monoclonal anti-IL-17A antibody and the first in its class to be approved by the US Food and Drug Administration for the treatment of moderate to severe plaque psoriasis.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    IL Receptor
  • Recptor
    IL Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    875356-43-7
  • Formula Weight
    151 kDa
  • Molecular Formula
    ——
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    ——
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Frieder J, et al.Secukinumab: a review of the anti-IL-17A biologic for the treatment of psoriasis.Ther Adv Chronic Dis. 2018 Jan;9(1):5-21.
molnova catalog
related products
  • Hispidulin 7-glucuro...

    Hispidulin 7-glucuronide is a flavonoid that can be extracted from the leaves of mistletoe and has potential anti-inflammatory activity, inhibiting the release of IL-6.

  • Guselkumab

    Guselkumab (CNTO 1959) is a recombinant human IgG1 monoclonal antibody targeting the IL-23p19 subunit.

  • SP 4206

    SP 4206 is a high-affinity (Kd=70 nM) small molecule that blocks blocks the binding of the IL-2α receptor (IL-2Rα) to IL-2.